



**Basel, Switzerland, June 25, 2025** – Landmark BioVentures (LBV) today announced key updates to its Executive team and Board of Directors as the company transitions into its next phase of strategic growth and development.

Early members, Dr. Samson Fung and Dr. Jacques Bauer will be moving on from LBV as Board members and Executive members. "We are grateful to both Samson and Jacques for their support in developing Landmark BioVentures and their contribution to our nexus," said Zaki Sellam, Co-founder and Chairman of Landmark BioVentures. "We wish them the best in their future endeavors and are confident that we can continue to rely on their technical and industry expertise whenever needed."

As part of this transition, Landmark BioVentures is pleased to welcome Dr. Josh Pan to its Board of Directors and as Executive team member. Dr. Pan brings a wealth of experience in corporate strategy, business development, fundraising, and investor and public relations. "Josh's appointment marks an exciting step forward for us," said Sellam. "He brings extensive biotech experience and a strategic presence in the U.S. with an initial anchor in Seattle, WA, which aligns with our global expansion plans. His deep experience in biotech startups, both as an investor and entrepreneur, along with his strong network, will be instrumental as LBV enters this next chapter of innovation and growth."

Additionally, Dr. Pan shared, "From my first conversations with the LBV team, it was clear our values and vision were deeply aligned. LBV's forward-thinking model reflects what our industry needs: an integrated, efficient, urgent, and innovative approach to drug development with meaningful impact for patients."

*Landmark BioVenture mission: Creatively & efficiently develop life-changing medicines to deliver a lasting impact.*